Xience Skypoint Everolimus Eluting Coronary Stent System
Abbott Vascular · Decision date Nov 1, 2011
What did the FDA approve?
The FDA database entry for P110019 records an original PMA approval dated November 1, 2011, for the Xience Prime and Xience Prime LL Everolimus Eluting Coronary Stent System. The stated purpose is improving coronary luminal diameter in patients with symptomatic heart disease due to de novo native coronary artery lesions of length 32 mm or less, with reference vessel diameters from 2.25 mm to 4.25 mm.
The entry lists Abbott Vascular as the applicant and classifies the device under product code NIQ as a coronary drug-eluting stent in the cardiovascular specialty. No supplement type or supplement reason is recorded, so the decision reflects the original approval scope rather than a later change. The source statement reports an indicated use but does not itself provide independent proof of safety or clinical effectiveness.
FDA approval order statement
APPROVAL FOR THE XIENCE PRIME AND XIENCE PRIME LL EVEROLIMUS ELUTING CORONARY STENT SYSTEM. THIS DEVICE IS INDICATED FOR IMPROVING CORONARY LUMINAL DIAMETER IN PATIENTS WITH SYMPTOMATIC HEART DISEASE DUE TO DE NOVO NATIVE CORONARY ARTERY LESIONS (LENGTH <= 32 MM) WITH REFERENCE VESSEL DIAMETERS OF >= 2.25 MM TO <= 4.25 MM.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Nov 1, 2011
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P110019
- Regulatory pathway
- Premarket approval application
- Applicant
- Abbott Vascular
- Product code
- NIQ
- Decision code
- APPR
- Decision date
- Nov 1, 2011
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Coronary drug-eluting stent.
- Applicant
- Abbott Vascular
- Product code
- NIQ
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P110019 received
Application receipt date recorded by FDA.
P110019 · FDA decision
APPR
P110019/S145 · Related supplement
XIENCE PRO5 Everolimus Eluting Coronary Stent System (XIENCE PRO5), XIENCE Skypoint Everolimus Eluting Coronary Stent Sy
Timeline entries are records held by MedtechLedger for P110019. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P110019
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Abbott Vascular | PMA supplement | Oct 1, 2026 | FDA |
Explore the linked device profile
Other records with product code NIQ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic Vascular | PMA supplement | Oct 16, 2026 | FDA | |
ORSIRO Sirolimus Eluting Coronary Stent SystemP170030/S066 | Biotronik AG | PMA supplement | Sep 24, 2026 | FDA |
| Biotronik AG | PMA approval | Feb 22, 2019 | FDA | |
| Medtronic Vascular | PMA approval | Apr 28, 2017 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Vascular
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 3200 Lakeside Dr., Santa Clara, CA, 95054
Sources and methodology
- Original FDA record: P110019
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



